IL271515A - Multispecific antibodies that specifically bind to Zika virus epitopes and their uses - Google Patents
Multispecific antibodies that specifically bind to Zika virus epitopes and their usesInfo
- Publication number
- IL271515A IL271515A IL271515A IL27151519A IL271515A IL 271515 A IL271515 A IL 271515A IL 271515 A IL271515 A IL 271515A IL 27151519 A IL27151519 A IL 27151519A IL 271515 A IL271515 A IL 271515A
- Authority
- IL
- Israel
- Prior art keywords
- specifically binding
- multispecific antibodies
- zika virus
- antibodies specifically
- virus epitopes
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
- C07K16/116—Togaviridae (F); Matonaviridae (F); Flaviviridae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/18—Togaviridae; Flaviviridae
- G01N2333/183—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
- G01N2333/185—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/26—Infectious diseases, e.g. generalised sepsis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Plant Pathology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2017/071891 WO2019042555A1 (en) | 2017-08-31 | 2017-08-31 | MULTISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO ZIKA VIRUS EPITOPES AND USES THEREOF |
| PCT/EP2018/073489 WO2019043166A1 (en) | 2017-08-31 | 2018-08-31 | MULTISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO ZIKA VIRUS EPITOPES AND USES THEREOF |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL271515A true IL271515A (en) | 2020-02-27 |
Family
ID=59811299
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL271515A IL271515A (en) | 2017-08-31 | 2019-12-17 | Multispecific antibodies that specifically bind to Zika virus epitopes and their uses |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US11926658B2 (enExample) |
| EP (1) | EP3676290A1 (enExample) |
| JP (2) | JP7244489B2 (enExample) |
| KR (1) | KR20200042499A (enExample) |
| CN (2) | CN116693668A (enExample) |
| AU (1) | AU2018322842A1 (enExample) |
| BR (1) | BR112020000619A2 (enExample) |
| CA (1) | CA3070780A1 (enExample) |
| CL (1) | CL2020000467A1 (enExample) |
| CO (1) | CO2020002060A2 (enExample) |
| CR (1) | CR20200087A (enExample) |
| DO (1) | DOP2020000043A (enExample) |
| EA (1) | EA202090559A1 (enExample) |
| EC (1) | ECSP20014362A (enExample) |
| IL (1) | IL271515A (enExample) |
| MX (1) | MX2020002181A (enExample) |
| MY (1) | MY201774A (enExample) |
| PE (1) | PE20200888A1 (enExample) |
| PH (1) | PH12020550025A1 (enExample) |
| SG (1) | SG11202000206SA (enExample) |
| WO (2) | WO2019042555A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019042555A1 (en) * | 2017-08-31 | 2019-03-07 | Humabs Biomed Sa | MULTISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO ZIKA VIRUS EPITOPES AND USES THEREOF |
| MY202505A (en) | 2017-11-03 | 2024-05-01 | Takeda Vaccines Inc | Zika vaccines and immunogenic compositions, and methods of using the same |
| SG11202003975WA (en) | 2017-11-30 | 2020-06-29 | Takeda Vaccines Inc | Method for inactivating zika virus and related methods |
| JP7725465B2 (ja) * | 2019-11-07 | 2025-08-19 | 中国科学院微生物研究所 | ジカ・デングワクチン及びその使用 |
| KR102365464B1 (ko) * | 2019-12-24 | 2022-02-22 | 강원대학교산학협력단 | 지카바이러스 재조합 서브유닛 백신의 개발 및 이의 제조방법 |
| WO2021236225A1 (en) * | 2020-05-20 | 2021-11-25 | Takeda Vaccines, Inc. | Method for detection of zika virus specific antibodies |
| US20230324404A1 (en) * | 2020-05-20 | 2023-10-12 | Takeda Vaccines, Inc. | Method for detection of zika virus specific antibodies |
| CN115697392B (zh) * | 2020-06-28 | 2026-03-13 | 神州细胞工程有限公司 | 一种降低病毒ade效应的方法 |
| WO2022109443A1 (en) * | 2020-11-23 | 2022-05-27 | The Regents Of The University Of Michigan | Single-chain antibody against flavivirus ns1 protein |
| CN114958747B (zh) * | 2022-06-08 | 2024-08-20 | 中国科学院动物研究所 | 一种多能干细胞诱导产生兴奋性和抑制性神经元的方法 |
| WO2025107050A1 (pt) * | 2023-11-23 | 2025-05-30 | Imunotera Soluções Terapêuticas Ltda | Anticorpo monoclonal, vetor de expressão, uso, composição farmacêutica, processo para produção, método de prevenção e/ou tratamento de infecções por flavivírus e kit para a detecção de vírus da zika e da dengue |
| CN119119256B (zh) * | 2024-09-28 | 2025-07-18 | 宁波大学 | 一种乙型脑炎病毒和寨卡病毒的单克隆抗体及其应用 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3766162A (en) | 1971-08-24 | 1973-10-16 | Hoffmann La Roche | Barbituric acid antigens and antibodies specific therefor |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4233402A (en) | 1978-04-05 | 1980-11-11 | Syva Company | Reagents and method employing channeling |
| JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
| US4609546A (en) | 1982-06-24 | 1986-09-02 | Japan Chemical Research Co., Ltd. | Long-acting composition |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US4831175A (en) | 1986-09-05 | 1989-05-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
| US5595721A (en) | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
| MY133346A (en) | 1999-03-01 | 2007-11-30 | Biogen Inc | Kit for radiolabeling ligands with yttrium-90 |
| US20020102208A1 (en) | 1999-03-01 | 2002-08-01 | Paul Chinn | Radiolabeling kit and binding assay |
| US7700097B2 (en) | 2003-06-27 | 2010-04-20 | Biogen Idec Ma Inc. | Purification and preferential synthesis of binding molecules |
| MX2009012343A (es) | 2007-05-14 | 2010-02-10 | Biogen Idec Inc | Regiones fc (sc fc) de cadena sencilla, polipeptidos de enlace que comprenden las mismas, y metodos relacionados con ello. |
| AU2014374055B2 (en) | 2013-12-30 | 2018-11-08 | Epimab Biotherapeutics Inc. | Fabs-in-tandem immunoglobulin and uses thereof |
| EP2980099A1 (en) * | 2014-07-31 | 2016-02-03 | Bernhard-Nocht-Institut für Tropenmedizin | Compositions and methods for detecting flaviviridae infections |
| CA2992531C (en) | 2015-07-16 | 2023-09-26 | Bharat Biotech International Limited | Vaccine compositions |
| BR112018068342A2 (pt) | 2016-03-11 | 2019-01-15 | Univ Johns Hopkins | vacina de vírus zika vivo atenuado |
| CN105954512A (zh) | 2016-06-01 | 2016-09-21 | 卢氏实验室公司 | 一种快速免疫层析法检测塞卡病毒Zika virus的检测条 |
| WO2018010789A1 (en) | 2016-07-13 | 2018-01-18 | Humabs Biomed Sa | Novel antibodies specifically binding to zika virus epitopes and uses thereof |
| TW201815821A (zh) | 2016-07-18 | 2018-05-01 | 美商再生元醫藥公司 | 抗茲卡病毒抗體及使用方法 |
| CN106279409B (zh) | 2016-08-10 | 2019-11-26 | 中国科学院微生物研究所 | 一种寨卡病毒人源单克隆抗体及其应用 |
| WO2018081755A1 (en) * | 2016-10-29 | 2018-05-03 | University Of Miami | Zika virus antibodies |
| EP3534953A4 (en) * | 2016-11-02 | 2020-10-07 | Vanderbilt University | ANTIBODIES AGAINST HUMAN ZIKA VIRUS AND THEIR USE PROCEDURES |
| CN106841601A (zh) | 2016-12-30 | 2017-06-13 | 广州市达瑞生物技术股份有限公司 | 寨卡病毒多片段融合蛋白的制备及IgG/IgM抗体检测试剂盒 |
| CN106885903B (zh) | 2017-03-08 | 2018-12-28 | 中国人民解放军军事医学科学院基础医学研究所 | 一种寨卡病毒e抗原及其在检测抗寨卡病毒抗体中的应用 |
| WO2019042555A1 (en) * | 2017-08-31 | 2019-03-07 | Humabs Biomed Sa | MULTISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO ZIKA VIRUS EPITOPES AND USES THEREOF |
-
2017
- 2017-08-31 WO PCT/EP2017/071891 patent/WO2019042555A1/en not_active Ceased
-
2018
- 2018-08-31 MX MX2020002181A patent/MX2020002181A/es unknown
- 2018-08-31 JP JP2020507007A patent/JP7244489B2/ja active Active
- 2018-08-31 PE PE2020000287A patent/PE20200888A1/es unknown
- 2018-08-31 CR CR20200087A patent/CR20200087A/es unknown
- 2018-08-31 EP EP18762834.2A patent/EP3676290A1/en not_active Withdrawn
- 2018-08-31 BR BR112020000619-0A patent/BR112020000619A2/pt not_active IP Right Cessation
- 2018-08-31 WO PCT/EP2018/073489 patent/WO2019043166A1/en not_active Ceased
- 2018-08-31 MY MYPI2019007495A patent/MY201774A/en unknown
- 2018-08-31 SG SG11202000206SA patent/SG11202000206SA/en unknown
- 2018-08-31 EA EA202090559A patent/EA202090559A1/ru unknown
- 2018-08-31 CN CN202310134988.XA patent/CN116693668A/zh active Pending
- 2018-08-31 CN CN201880057824.9A patent/CN111344302B/zh active Active
- 2018-08-31 KR KR1020207007493A patent/KR20200042499A/ko not_active Abandoned
- 2018-08-31 CA CA3070780A patent/CA3070780A1/en active Pending
- 2018-08-31 AU AU2018322842A patent/AU2018322842A1/en not_active Abandoned
- 2018-08-31 US US16/640,622 patent/US11926658B2/en active Active
-
2019
- 2019-12-17 IL IL271515A patent/IL271515A/en unknown
-
2020
- 2020-01-16 PH PH12020550025A patent/PH12020550025A1/en unknown
- 2020-02-26 CL CL2020000467A patent/CL2020000467A1/es unknown
- 2020-02-26 CO CONC2020/0002060A patent/CO2020002060A2/es unknown
- 2020-02-26 DO DO2020000043A patent/DOP2020000043A/es unknown
- 2020-02-27 EC ECSENADI202014362A patent/ECSP20014362A/es unknown
-
2023
- 2023-03-09 JP JP2023036084A patent/JP2023071956A/ja not_active Withdrawn
-
2024
- 2024-02-22 US US18/584,654 patent/US20240254207A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ECSP20014362A (es) | 2020-04-22 |
| JP2020531000A (ja) | 2020-11-05 |
| PH12020550025A1 (en) | 2021-02-15 |
| US20200317755A1 (en) | 2020-10-08 |
| PE20200888A1 (es) | 2020-09-03 |
| JP7244489B2 (ja) | 2023-03-22 |
| WO2019043166A1 (en) | 2019-03-07 |
| CN111344302A (zh) | 2020-06-26 |
| WO2019042555A1 (en) | 2019-03-07 |
| CN111344302B (zh) | 2023-03-10 |
| MX2020002181A (es) | 2020-07-20 |
| BR112020000619A2 (pt) | 2020-07-14 |
| US11926658B2 (en) | 2024-03-12 |
| CN116693668A (zh) | 2023-09-05 |
| SG11202000206SA (en) | 2020-03-30 |
| AU2018322842A1 (en) | 2020-01-16 |
| CR20200087A (es) | 2020-08-07 |
| MY201774A (en) | 2024-03-16 |
| CO2020002060A2 (es) | 2020-06-09 |
| EA202090559A1 (ru) | 2020-06-17 |
| US20240254207A1 (en) | 2024-08-01 |
| CL2020000467A1 (es) | 2020-06-19 |
| CA3070780A1 (en) | 2019-03-07 |
| JP2023071956A (ja) | 2023-05-23 |
| EP3676290A1 (en) | 2020-07-08 |
| KR20200042499A (ko) | 2020-04-23 |
| DOP2020000043A (es) | 2020-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LT3484915T (lt) | Naujo tipo antikūnai, specifiškai susirišantys su zika viruso epitopais, ir jų panaudojimas | |
| SG11202000206SA (en) | Multispecific antibodies specifically binding to zika virus epitopes and uses thereof | |
| ZA201906813B (en) | Antibody binding specifically to muc1 and use thereof | |
| ZA201903848B (en) | Antibodies that specifically bind to human il-15 and uses thereof | |
| ZA201905341B (en) | Antibodies specifically binding to human il-1r7 | |
| SG11202007578SA (en) | Antibodies binding to gprc5d | |
| IL268243A (en) | Antibodies to alpha-synuclein and their uses | |
| ZA201803669B (en) | Antibodies specifically binding pd-1 and their uses | |
| ZA201808582B (en) | Antibodies to alpha-synuclein and uses thereof | |
| IL249266B (en) | Trispecific molecules that bind multiple cancer antigens and methods of using them | |
| IL247221A0 (en) | Antibodies that bind to the dengue virus, preparations containing them and their uses | |
| IL275471A (en) | Antibodies bind to HLA-A2/WT1 | |
| ZA201902120B (en) | Antibody specifically binding to pd-1 and functional fragment thereof | |
| IL269394A (en) | Antibodies bind to STEAP-1 | |
| IL244237A0 (en) | Bispecific monovalent diabodies capable of binding to cd123 and cd3 and their uses | |
| IL266516B (en) | An antibody that specifically binds to cd66c and its use | |
| SG10201912925SA (en) | Antibodies that bind zika virus envelope protein and uses thereof | |
| SG11201704500VA (en) | Antibody binding to neuropilin 1 and use thereof | |
| EP3225628A4 (en) | Epitope of hepatitis b virus surface antigen and binding molecule specifically binding to same for neutralizing hepatitis b virus | |
| PL3362480T3 (pl) | Przeciwciało specyficznie wiążące się z ERBB3 i jego zastosowanie | |
| ZA202001042B (en) | Antibody specifically binding to pauf protein, and use thereof |